Review



rabbit polyclonal anti rim bp2 antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Proteintech rabbit polyclonal anti rim bp2 antibody
    Rabbit Polyclonal Anti Rim Bp2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+rim+bp2+antibody/RIMBP2+Antibody/pmc12462525__42003_2025_8747_MOESM1_ESM-3-73-83
    Average 93 stars, based on 3 article reviews
    rabbit polyclonal anti rim bp2 antibody - by Bioz Stars, 2026-09
    93/100 stars

    Images



    Similar Products

    rabbit polyclonal anti rim bp2 antibody  (Proteintech)
    93
    Proteintech rabbit polyclonal anti rim bp2 antibody
    Rabbit Polyclonal Anti Rim Bp2 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+rim+bp2+antibody/RIMBP2+Antibody/pmc12462525__42003_2025_8747_MOESM1_ESM-3-73-83
    Average 93 stars, based on 1 article reviews
    rabbit polyclonal anti rim bp2 antibody - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    antibody anti rim bp2 rabbit polyclonal proteintech  (Proteintech)
    93
    Proteintech antibody anti rim bp2 rabbit polyclonal proteintech
    Antibody Anti Rim Bp2 Rabbit Polyclonal Proteintech, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+rim+bp2+antibody/RIMBP2+Antibody/10__7554_slash_elife__82821-227-59-65
    Average 93 stars, based on 1 article reviews
    antibody anti rim bp2 rabbit polyclonal proteintech - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti-rim-bp2  (Synaptic Systems)
    90
    Synaptic Systems rabbit polyclonal anti-rim-bp2
    Rescue experiments using lentiviruses expressing target shRNA-resistant proteins show specificity in the target shRNA-derived synaptogenic effects driven by Slitrk6 or Nlgn1 in heterologous synapse formation analyses. A, Representative images of heterologous synapse-formation activities of Nlgn1 and Slitrk6. Cultured hippocampal neurons were infected with the indicated protein KD lentiviruses and/or the target-specific rescue expression lentiviruses at DIV4 and cocultured with Nlgn1- or Slitrk6-expressing HEK293T cells for 12 h (Nlgn1; DIV11-12) or 24 h (Slitrk6; DIV12). Hemi-synapse induction was analyzed by double-immunostaining for HA/EGFP (blue) and VGLUT1 (red). Scale bar, 10 μm. CSK1, Caskin-1; RBP2, <t>RIM-BP2.</t> For expression levels of the shRNA-resistant vectors used in Figure 5, see Extended Data Figure 5-1. B, Quantification of synapse-formation activity in A by measuring the ratio of red staining intensity to blue staining intensity. Data are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA with a nonparametric Kruskal–Wallis test. n indicates the number of cells as follows: sh-Control/Slitrk6/VGLUT1, n = 26; sh-MIM-B/Slitrk6/VGLUT1, n = 14; + MIM-B (res)/Slitrk6/VGLUT1, n = 12; sh-Caskins/Slitrk6/VGLUT1, n = 17; + CSK1 (res)/Slitrk6/VGLUT1, n = 12; sh-Abl/Slitrk6/VGLUT1, n = 14; + Abl1 (res)/Slitrk6/VGLUT1, n = 16; sh-Ena/Slitrk6/VGLUT1, n = 14; + Ena (res)/Slitrk6/VGLUT1, n = 13; sh-ELKS/Slitrk6/VGLUT1, n = 13; + ELKS2 (res)/Slitrk6/VGLUT1, n = 19; sh-SYD1A/Slitrk6/VGLUT1, n = 16; + SYD1A (res)/Slitrk6/VGLUT1, n = 11; sh-CASK/Slitrk6/VGLUT1, n = 13; + CASK (res)/Slitrk6/VGLUT1, n = 15; sh-RIM-BPs/Slitrk6/VGLUT1, n = 15; + RBP2 (res)/Slitrk6/VGLUT1, n = 14; sh-Control/Nlgn1/VGLUT1, n = 23; sh-MIM-B/Nlgn1/VGLUT1, n = 13; + MIM-B (res)/Nlgn1/VGLUT1, n = 19; sh-Caskins/Nlgn1/VGLUT1, n = 20; + CSK1 (res)/Nlgn1/VGLUT1, n = 17; sh-Abl/Nlgn1/VGLUT1, n = 15; + Abl1 (res)/Nlgn1/VGLUT1, n = 19; sh-Ena/Nlgn1/VGLUT1, n = 17; + Ena (res)/Nlgn1/VGLUT1, n = 18; sh-ELKS/Nlgn1/VGLUT1, n = 16; + ELKS2 (res)/Nlgn1/VGLUT1, n = 15; sh-SYD1A/Nlgn1/VGLUT1, n = 14; + SYD1A (res)/Nlgn1/VGLUT1, n = 23; sh-CASK/Nlgn1/VGLUT1, n = 18; + CASK (res)/Nlgn1/VGLUT1, n = 20; sh-RIM-BPs/Nlgn1/VGLUT1, n = 19; and + RBP2 (res)/Nlgn1/VGLUT1, n = 15. p values for each comparison are as follows: sh-Control versus sh-MIM-B/Slitrk6/VGLUT1, p = 0.9366; sh-Control versus + MIM-B (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-Caskins/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + CSK1 (res)/Slitrk6/VGLUT1, p = 0.7744; sh-Control versus sh-Abl/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + Abl1 (res)/Slitrk6/VGLUT1, p = 0.8745; sh-Control versus sh-Ena/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + Ena (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-ELKS/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + ELKS2 (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-SYD1A/Slitrk6/VGLUT1, p = 0.0195; sh-Control versus + SYD1A (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-CASK/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + CASK (res)/Slitrk6/VGLUT1, p = 0.6365; sh-Control versus sh-RIM-BPs/Slitrk6/VGLUT1, p = 0.0006; sh-Control versus + RBP2 (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-MIM-B/Nlgn1/VGLUT1, p = 0.0006; sh-Control versus + MIM-B (res)/Nlgn1/VGLUT1, p = 0.8354; sh-Control versus sh-Caskins/Nlgn1/VGLUT1, p = 0.6949; sh-Control versus + CSK1 (res)/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus sh-Abl/Nlgn1/VGLUT1, p = 0.0006; sh-Control versus + Abl1 (res)/Nlgn1/VGLUT1, p = 0.3353; sh-Control versus sh-Ena/Nlgn1/VGLUT1, p = 0.0001; sh-Control versus + Ena (res)/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus sh-ELKS/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus + ELKS2 (res)/Nlgn1/VGLUT1, p = 0.9148; sh-Control versus sh-SYD1A/Nlgn1/VGLUT1, p = 0.0060; sh-Control versus + SYD1A (res)/Nlgn1/VGLUT1, p > 0.9999; sh-CASK/Nlgn1/VGLUT1, p = 0.3146; sh-Control versus + CASK (res)/Nlgn1/VGLUT1, p = 0.0628; sh-Control versus sh-RIM-BPs/Nlgn1/VGLUT1, p = 0.0013; and sh-Control versus + RBP2 (res)/Nlgn1/VGLUT1, p > 0.9999. CSK1, Caskin-1; RBP2, RIM-BP2.
    Rabbit Polyclonal Anti Rim Bp2, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+rim+bp2+antibody/rabbit+polyclonal+anti+rim+bp2/pmc07605416-443-94-97
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal anti-rim-bp2 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Rescue experiments using lentiviruses expressing target shRNA-resistant proteins show specificity in the target shRNA-derived synaptogenic effects driven by Slitrk6 or Nlgn1 in heterologous synapse formation analyses. A, Representative images of heterologous synapse-formation activities of Nlgn1 and Slitrk6. Cultured hippocampal neurons were infected with the indicated protein KD lentiviruses and/or the target-specific rescue expression lentiviruses at DIV4 and cocultured with Nlgn1- or Slitrk6-expressing HEK293T cells for 12 h (Nlgn1; DIV11-12) or 24 h (Slitrk6; DIV12). Hemi-synapse induction was analyzed by double-immunostaining for HA/EGFP (blue) and VGLUT1 (red). Scale bar, 10 μm. CSK1, Caskin-1; RBP2, RIM-BP2. For expression levels of the shRNA-resistant vectors used in Figure 5, see Extended Data Figure 5-1. B, Quantification of synapse-formation activity in A by measuring the ratio of red staining intensity to blue staining intensity. Data are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA with a nonparametric Kruskal–Wallis test. n indicates the number of cells as follows: sh-Control/Slitrk6/VGLUT1, n = 26; sh-MIM-B/Slitrk6/VGLUT1, n = 14; + MIM-B (res)/Slitrk6/VGLUT1, n = 12; sh-Caskins/Slitrk6/VGLUT1, n = 17; + CSK1 (res)/Slitrk6/VGLUT1, n = 12; sh-Abl/Slitrk6/VGLUT1, n = 14; + Abl1 (res)/Slitrk6/VGLUT1, n = 16; sh-Ena/Slitrk6/VGLUT1, n = 14; + Ena (res)/Slitrk6/VGLUT1, n = 13; sh-ELKS/Slitrk6/VGLUT1, n = 13; + ELKS2 (res)/Slitrk6/VGLUT1, n = 19; sh-SYD1A/Slitrk6/VGLUT1, n = 16; + SYD1A (res)/Slitrk6/VGLUT1, n = 11; sh-CASK/Slitrk6/VGLUT1, n = 13; + CASK (res)/Slitrk6/VGLUT1, n = 15; sh-RIM-BPs/Slitrk6/VGLUT1, n = 15; + RBP2 (res)/Slitrk6/VGLUT1, n = 14; sh-Control/Nlgn1/VGLUT1, n = 23; sh-MIM-B/Nlgn1/VGLUT1, n = 13; + MIM-B (res)/Nlgn1/VGLUT1, n = 19; sh-Caskins/Nlgn1/VGLUT1, n = 20; + CSK1 (res)/Nlgn1/VGLUT1, n = 17; sh-Abl/Nlgn1/VGLUT1, n = 15; + Abl1 (res)/Nlgn1/VGLUT1, n = 19; sh-Ena/Nlgn1/VGLUT1, n = 17; + Ena (res)/Nlgn1/VGLUT1, n = 18; sh-ELKS/Nlgn1/VGLUT1, n = 16; + ELKS2 (res)/Nlgn1/VGLUT1, n = 15; sh-SYD1A/Nlgn1/VGLUT1, n = 14; + SYD1A (res)/Nlgn1/VGLUT1, n = 23; sh-CASK/Nlgn1/VGLUT1, n = 18; + CASK (res)/Nlgn1/VGLUT1, n = 20; sh-RIM-BPs/Nlgn1/VGLUT1, n = 19; and + RBP2 (res)/Nlgn1/VGLUT1, n = 15. p values for each comparison are as follows: sh-Control versus sh-MIM-B/Slitrk6/VGLUT1, p = 0.9366; sh-Control versus + MIM-B (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-Caskins/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + CSK1 (res)/Slitrk6/VGLUT1, p = 0.7744; sh-Control versus sh-Abl/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + Abl1 (res)/Slitrk6/VGLUT1, p = 0.8745; sh-Control versus sh-Ena/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + Ena (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-ELKS/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + ELKS2 (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-SYD1A/Slitrk6/VGLUT1, p = 0.0195; sh-Control versus + SYD1A (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-CASK/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + CASK (res)/Slitrk6/VGLUT1, p = 0.6365; sh-Control versus sh-RIM-BPs/Slitrk6/VGLUT1, p = 0.0006; sh-Control versus + RBP2 (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-MIM-B/Nlgn1/VGLUT1, p = 0.0006; sh-Control versus + MIM-B (res)/Nlgn1/VGLUT1, p = 0.8354; sh-Control versus sh-Caskins/Nlgn1/VGLUT1, p = 0.6949; sh-Control versus + CSK1 (res)/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus sh-Abl/Nlgn1/VGLUT1, p = 0.0006; sh-Control versus + Abl1 (res)/Nlgn1/VGLUT1, p = 0.3353; sh-Control versus sh-Ena/Nlgn1/VGLUT1, p = 0.0001; sh-Control versus + Ena (res)/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus sh-ELKS/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus + ELKS2 (res)/Nlgn1/VGLUT1, p = 0.9148; sh-Control versus sh-SYD1A/Nlgn1/VGLUT1, p = 0.0060; sh-Control versus + SYD1A (res)/Nlgn1/VGLUT1, p > 0.9999; sh-CASK/Nlgn1/VGLUT1, p = 0.3146; sh-Control versus + CASK (res)/Nlgn1/VGLUT1, p = 0.0628; sh-Control versus sh-RIM-BPs/Nlgn1/VGLUT1, p = 0.0013; and sh-Control versus + RBP2 (res)/Nlgn1/VGLUT1, p > 0.9999. CSK1, Caskin-1; RBP2, RIM-BP2.

    Journal: The Journal of Neuroscience

    Article Title: LAR-RPTPs Directly Interact with Neurexins to Coordinate Bidirectional Assembly of Molecular Machineries

    doi: 10.1523/JNEUROSCI.1091-20.2020

    Figure Lengend Snippet: Rescue experiments using lentiviruses expressing target shRNA-resistant proteins show specificity in the target shRNA-derived synaptogenic effects driven by Slitrk6 or Nlgn1 in heterologous synapse formation analyses. A, Representative images of heterologous synapse-formation activities of Nlgn1 and Slitrk6. Cultured hippocampal neurons were infected with the indicated protein KD lentiviruses and/or the target-specific rescue expression lentiviruses at DIV4 and cocultured with Nlgn1- or Slitrk6-expressing HEK293T cells for 12 h (Nlgn1; DIV11-12) or 24 h (Slitrk6; DIV12). Hemi-synapse induction was analyzed by double-immunostaining for HA/EGFP (blue) and VGLUT1 (red). Scale bar, 10 μm. CSK1, Caskin-1; RBP2, RIM-BP2. For expression levels of the shRNA-resistant vectors used in Figure 5, see Extended Data Figure 5-1. B, Quantification of synapse-formation activity in A by measuring the ratio of red staining intensity to blue staining intensity. Data are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA with a nonparametric Kruskal–Wallis test. n indicates the number of cells as follows: sh-Control/Slitrk6/VGLUT1, n = 26; sh-MIM-B/Slitrk6/VGLUT1, n = 14; + MIM-B (res)/Slitrk6/VGLUT1, n = 12; sh-Caskins/Slitrk6/VGLUT1, n = 17; + CSK1 (res)/Slitrk6/VGLUT1, n = 12; sh-Abl/Slitrk6/VGLUT1, n = 14; + Abl1 (res)/Slitrk6/VGLUT1, n = 16; sh-Ena/Slitrk6/VGLUT1, n = 14; + Ena (res)/Slitrk6/VGLUT1, n = 13; sh-ELKS/Slitrk6/VGLUT1, n = 13; + ELKS2 (res)/Slitrk6/VGLUT1, n = 19; sh-SYD1A/Slitrk6/VGLUT1, n = 16; + SYD1A (res)/Slitrk6/VGLUT1, n = 11; sh-CASK/Slitrk6/VGLUT1, n = 13; + CASK (res)/Slitrk6/VGLUT1, n = 15; sh-RIM-BPs/Slitrk6/VGLUT1, n = 15; + RBP2 (res)/Slitrk6/VGLUT1, n = 14; sh-Control/Nlgn1/VGLUT1, n = 23; sh-MIM-B/Nlgn1/VGLUT1, n = 13; + MIM-B (res)/Nlgn1/VGLUT1, n = 19; sh-Caskins/Nlgn1/VGLUT1, n = 20; + CSK1 (res)/Nlgn1/VGLUT1, n = 17; sh-Abl/Nlgn1/VGLUT1, n = 15; + Abl1 (res)/Nlgn1/VGLUT1, n = 19; sh-Ena/Nlgn1/VGLUT1, n = 17; + Ena (res)/Nlgn1/VGLUT1, n = 18; sh-ELKS/Nlgn1/VGLUT1, n = 16; + ELKS2 (res)/Nlgn1/VGLUT1, n = 15; sh-SYD1A/Nlgn1/VGLUT1, n = 14; + SYD1A (res)/Nlgn1/VGLUT1, n = 23; sh-CASK/Nlgn1/VGLUT1, n = 18; + CASK (res)/Nlgn1/VGLUT1, n = 20; sh-RIM-BPs/Nlgn1/VGLUT1, n = 19; and + RBP2 (res)/Nlgn1/VGLUT1, n = 15. p values for each comparison are as follows: sh-Control versus sh-MIM-B/Slitrk6/VGLUT1, p = 0.9366; sh-Control versus + MIM-B (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-Caskins/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + CSK1 (res)/Slitrk6/VGLUT1, p = 0.7744; sh-Control versus sh-Abl/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + Abl1 (res)/Slitrk6/VGLUT1, p = 0.8745; sh-Control versus sh-Ena/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + Ena (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-ELKS/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + ELKS2 (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-SYD1A/Slitrk6/VGLUT1, p = 0.0195; sh-Control versus + SYD1A (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-CASK/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus + CASK (res)/Slitrk6/VGLUT1, p = 0.6365; sh-Control versus sh-RIM-BPs/Slitrk6/VGLUT1, p = 0.0006; sh-Control versus + RBP2 (res)/Slitrk6/VGLUT1, p > 0.9999; sh-Control versus sh-MIM-B/Nlgn1/VGLUT1, p = 0.0006; sh-Control versus + MIM-B (res)/Nlgn1/VGLUT1, p = 0.8354; sh-Control versus sh-Caskins/Nlgn1/VGLUT1, p = 0.6949; sh-Control versus + CSK1 (res)/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus sh-Abl/Nlgn1/VGLUT1, p = 0.0006; sh-Control versus + Abl1 (res)/Nlgn1/VGLUT1, p = 0.3353; sh-Control versus sh-Ena/Nlgn1/VGLUT1, p = 0.0001; sh-Control versus + Ena (res)/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus sh-ELKS/Nlgn1/VGLUT1, p > 0.9999; sh-Control versus + ELKS2 (res)/Nlgn1/VGLUT1, p = 0.9148; sh-Control versus sh-SYD1A/Nlgn1/VGLUT1, p = 0.0060; sh-Control versus + SYD1A (res)/Nlgn1/VGLUT1, p > 0.9999; sh-CASK/Nlgn1/VGLUT1, p = 0.3146; sh-Control versus + CASK (res)/Nlgn1/VGLUT1, p = 0.0628; sh-Control versus sh-RIM-BPs/Nlgn1/VGLUT1, p = 0.0013; and sh-Control versus + RBP2 (res)/Nlgn1/VGLUT1, p > 0.9999. CSK1, Caskin-1; RBP2, RIM-BP2.

    Article Snippet: The following antibodies were obtained commercially: mouse monoclonal anti-HA (clone 16B12; BioLegend, RRID: AB_2565006 ); rabbit polyclonal anti-HA (Sigma, RRID: AB_260070 ); mouse monoclonal anti-GAD67 (clone 1G10.2; Millipore, RRID: AB_2278725 ); rabbit polyclonal anti-VGLUT1 (Synaptic Systems, RRID: AB_887880 ); mouse monoclonal anti-PTPσ (clone 17G7.2; MediMabs; RRID: AB_1808357 ); rabbit polyclonal anti-Nlgn2 (Synaptic Systems, RRID: AB_993011 ); rabbit monoclonal anti-TrkC (clone C44H5; Cell Signaling; RRID: AB_2155283 ); rabbit monoclonal anti-Enah (Cell Signaling; RRID: AB_1031036 ); mouse monoclonal anti-ABL (clone 8E9; BD Bioscience; RRID: AB_2220994 ); rabbit polyclonal anti-GABA A γ2 (Synaptic Systems; RRID: AB_2263066 ); rabbit polyclonal anti-RIM-BP2 (Synaptic Systems 316 103; RRID: AB_2620052 ); rabbit polyclonal anti-SYD1A (Fitzgerald; RRID: AB_10811953 ); mouse monoclonal anti-CASK (clone K56A/50; NeuroMab, RRID: AB_2068730 ); mouse monoclonal anti-ELKS1 (clone ELKS-30; Sigma Millipore, RRID: AB_2100013 ); rabbit polyclonal anti-Nrxn1α antibody (Millipore; RRID: AB_10917110 ); and mouse monoclonal anti-Csp2 (Developmental Studies Hybridoma Bank, RRID: AB_10805296 ).

    Techniques: Expressing, shRNA, Derivative Assay, Cell Culture, Infection, Double Immunostaining, Activity Assay, Staining

    Lentiviral shRNA constructs used in the current study

    Journal: The Journal of Neuroscience

    Article Title: LAR-RPTPs Directly Interact with Neurexins to Coordinate Bidirectional Assembly of Molecular Machineries

    doi: 10.1523/JNEUROSCI.1091-20.2020

    Figure Lengend Snippet: Lentiviral shRNA constructs used in the current study

    Article Snippet: The following antibodies were obtained commercially: mouse monoclonal anti-HA (clone 16B12; BioLegend, RRID: AB_2565006 ); rabbit polyclonal anti-HA (Sigma, RRID: AB_260070 ); mouse monoclonal anti-GAD67 (clone 1G10.2; Millipore, RRID: AB_2278725 ); rabbit polyclonal anti-VGLUT1 (Synaptic Systems, RRID: AB_887880 ); mouse monoclonal anti-PTPσ (clone 17G7.2; MediMabs; RRID: AB_1808357 ); rabbit polyclonal anti-Nlgn2 (Synaptic Systems, RRID: AB_993011 ); rabbit monoclonal anti-TrkC (clone C44H5; Cell Signaling; RRID: AB_2155283 ); rabbit monoclonal anti-Enah (Cell Signaling; RRID: AB_1031036 ); mouse monoclonal anti-ABL (clone 8E9; BD Bioscience; RRID: AB_2220994 ); rabbit polyclonal anti-GABA A γ2 (Synaptic Systems; RRID: AB_2263066 ); rabbit polyclonal anti-RIM-BP2 (Synaptic Systems 316 103; RRID: AB_2620052 ); rabbit polyclonal anti-SYD1A (Fitzgerald; RRID: AB_10811953 ); mouse monoclonal anti-CASK (clone K56A/50; NeuroMab, RRID: AB_2068730 ); mouse monoclonal anti-ELKS1 (clone ELKS-30; Sigma Millipore, RRID: AB_2100013 ); rabbit polyclonal anti-Nrxn1α antibody (Millipore; RRID: AB_10917110 ); and mouse monoclonal anti-Csp2 (Developmental Studies Hybridoma Bank, RRID: AB_10805296 ).

    Techniques: shRNA, Construct, Sequencing